Adamis Pharmaceuticals logo
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19
June 11, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of...
Adamis Pharmaceuticals logo
Adamis Provides Update on ZIMHI™
June 09, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s...
Adamis Pharmaceuticals logo
Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19
June 07, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
NIH Researchers Contend “Tempol may be a Promising Oral Antiviral Treatment for COVID-19” Research Team Intends to Conduct Additional Studies, Including a Prospective Clinical Study for Tempol in the...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Provides Business Update
June 01, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ
May 28, 2021 16:04 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, May 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call
May 17, 2021 16:05 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose
May 17, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Schedules First Quarter 2021 Financial Results Conference Call and Business Update
May 12, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Announces 2020 Financial Results and Business Update
April 15, 2021 16:39 ET | Adamis Pharmaceuticals Corporation
Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021 Management to host webcast/conference call...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update
April 13, 2021 16:03 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory...